Posts tagged PMN
Mackie starts Promis at speculative buy

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD). The stock closed at 25 cents on Sept. 18.

Read More
ProMIS names Johanne Kaplan as CDO

ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.

Read More
ProMIS in new program to identify ALS targets

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

“ProMIS will apply its proprietary computational algorithms, supplemented by other methods pioneered by ProMIS scientists, to identify specific therapeutic targets on misfolded TDP43,” SCO, Dr. Neil Cashman, said in a statement.

Read More
ProMIS announces new AZ program

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the development of Alzheimer’s disease (AD).

“With multiple product candidates in our Ab program progressing to final validation and selection for drug development, we are focusing our science team and discovery processes on the other half of the root cause – tau prions.” SCO, Dr. Neil Cashman, explained in a statement.

Read More